PerkinElmer Appoints Dr. John Sherwin to Lead Genetic Screening Laboratory Services

Distinguished Laboratory Director Joins Company to Drive Quality and Growth in Neonatal and Prenatal Service Business WALTHAM, Mass.–PerkinElmer, Inc. (NYSE: PKI – News), a global technology leader in Health Sciences and Photonics, today announced that John E. Sherwin, Ph.D., has joined the Company as director of laboratory operations for its genetic screening business, reporting to Ann-Christine Sundell, president of genetic screening, PerkinElmer, Inc. In this role, he is responsible for overseeing and directing the growth of PerkinElmer’s genetic screening laboratory services offerings, including PerkinElmer Genetics, Inc., a neonatal screening reference laboratory, and NTD Laboratories, a reference laboratory specializing in prenatal risk assessment. Dr. Sherwin brings more than 30 years of pediatric and perinatal laboratory medicine experience to his new position, including nearly 20 years directing laboratories at hospitals in Chicago and Fresno, California. He joins PerkinElmer from the State of California, where he most recently served as acting chief of the Genetic Disease Branch, responsible for the operation of the State’s entire prenatal and newborn screening program – the largest such program in the world. Prior to this, he was chief of the California Genetic Disease Laboratory for eight years. He has also held positions as senior technical director, general manager and chief operating officer of multimillion-dollar reference laboratories and has been a consultant to a variety of businesses and physician practices. “John is a talented clinician and seasoned laboratory director with the scientific and operations expertise needed to lead our genetic screening reference laboratories,” said Sundell. “We are fortunate to have someone with John’s experience join our team as we continue to expand our world-class neonatal and prenatal/maternal health solutions and services portfolio to help protect the health of mothers and babies around the world from pregnancy to birth and beyond.” Dr. Sherwin is a past president of both the American Association for Clinical Chemistry and the National Academy of Clinical Biochemistry, is active in the Association of Public Health Laboratories, and is a member of the governing council of the International Society for Newborn Screening. He holds a Ph.D. in biological science from the University of California, Santa Barbara and a bachelor’s degree in biology from the University of Arizona, Tucson. Factors Affecting Future Performance This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through or 1-877-PKI-NYSE.

< | >